Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Juniper Point
Deal Size : $72.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iro...
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Juniper Point
Deal Size : $72.0 million
Deal Type : Series B Financing
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial
Details : RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial
Details : RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2022
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $35.0 million
Deal Type : Series A Financing
Details : Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a ...
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 15, 2022
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $35.0 million
Deal Type : Series A Financing
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
Details : This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rénibus Therapeutics will present Phase 1b clinical trial data on RBT-1, its investigational treatment for the prevention of acute kidney injury (AKI), at the Acute Kidney Injury & Continuous Renal Replacement Therapy (AKI & CRRT) 2021 Conference.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2021
Lead Product(s) : Stannic Protoporfin,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association
Details : Based on the results to be presented at ERA-EDTA, the company is currently planning a Phase 2 study to investigate whether RBT-1 upregulates the expression of these biomarkers of cytoprotection in patients scheduled to undergo cardiac surgery.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stannus Protoporphyrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RBT-9 initially showcased broad antiviral activity against several enveloped viruses – as well as protective effects for vital organs, including the lungs, heart, kidneys and liver. RBT-9 inhibits viral activity of SARS-CoV-2, shows study conducted by ...
Product Name : RBT-9
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Stannus Protoporphyrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stannus Protoporphyrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Renibus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic
Details : RBT-9 is being developed by Renibus Therapeutics as an antiviral agent with organ-protective attributes. With the advent of the coronavirus pandemic, Renibus scientists moved quickly to plan and initiate a clinical trial of RBT-9 in COVID-19 patients.
Product Name : RBT-9
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : Stannus Protoporphyrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Renibus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration